News | 22 January 2022
Molnupiravir reduces risk of hospitalisation by 30% : Dr Shashank Joshi
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
Omicron patients below 60 with no comorbidities can start treatment with paracetamol
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
Biocon has reported consolidated financial results for the period ended December 31, 2021
However, these won’t be available at the nearest chemist store soon
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
They will commercialize molnupiravir in the international markets
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
This is the company’s first partnership arrangement in China
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
The acquisition would enable addition of established brands with high recall amongst healthcare professionals, especially in the vitamins, minerals and supplements category
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
The last date to apply for this program is 18th January 2022
ICICI Direct gives a preview on the earnings narrative for Q3FY22
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
This surpasses the number of approvals supported in 2020
Ind-Ra expects revenue growth of over 12% in 2022.
This advanced technology for Diabetic Foot Ulcer (DFU), management has a high scope of preventing amputations in diabetic patients. It has no definitive treatment in India. This technology will be available at affordable rates
The study will be published on the pre-print server, medRXiv, shortly
Subscribe To Our Newsletter & Stay Updated
